Dr. Gojo’s research focuses on the development and bi-directional translation of novel preclinical studies and insights into innovative biology-based phase I/II clinical trials for patients with AML, ALL, and MDS, accompanied by correlative mechanistic/biologic studies utilizing primary patient samples.